Madison Garibotti
PhD Candidate | York University
Muscle Health Research Centre, NSERC, Micas, Muscular Dystrophy Canada
NMD4C Involvement: NMD4C Collaborative Research Training Award (2025)
Email MadisonResearch Interests: Duchenne Muscular Dystrophy
Google Scholar profileLinkedIn profile
ResearchGate profile
Biography
Madison Garibotti is a PhD Candidate studying under Dr. Christopher Perry. Her PhD focus is on muscular and cardiac functional impairments in the early stages of Duchenne muscular dystrophy (DMD) and how these impairments affect cell function.
In 2025, Madison received the NMD4C Collaborative Research Training Award.
Recent Publications
Rihoux, A, Sutton, E, Lee, J, Flewwelling, L, Garibotti, M, Osman, H et al.. 2nd NMD4C basic research summer school on promoting standardized protocols to advance translational research in neuromuscular disorders. J Neuromuscul Dis. 2025. 22143602251408154 PMID:41417778
Khajehzadehshoushtar, S, Delfinis, LJ, Rahman, FA, Garibotti, MC, Gandhi, S, Brahmbhatt, AN et al.. The mitochondrial-targeted antioxidant SkQ1 prevents skeletal muscle mitochondrial-apoptotic but not necroptotic signalling during ovarian cancer. J Physiol. 2025. PMID:41177963
Delfinis, LJ, Khajehzadehshoushtar, S, Flewwelling, LD, Andrews, NJ, Garibotti, MC, Gandhi, S et al.. Mitochondrial-targeted plastoquinone therapy prevents early onset muscle weakness that occurs before atrophy during ovarian cancer. Mol Metab. 2025.99 102211 PMID:40681103
Gandhi, S, Delfinis, LJ, Bhatt, PD, Garibotti, MC, Bellissimo, CA, Goli, AN et al.. Adiponectin-receptor agonism prevents right ventricular tissue pathology in a mouse model of Duchenne muscular dystrophy. Mol Metab. 2025.99 102179 PMID:40490137
Delfinis, LJ, Khajehzadehshoushtar, S, Flewwelling, LD, Andrews, NJ, Garibotti, MC, Gandhi, S et al.. Mitochondrial-targeted plastoquinone therapy ameliorates early onset muscle weakness that precedes ovarian cancer cachexia in mice. bioRxiv. 2024. PMID:39484418
See more on PubMed